{
  "resourceType": "Observation",
  "id": "mii-exa-molgen-therapeutische-implikation-fgfr2-fusion",
  "meta": {
    "profile": [
      "https://www.medizininformatik-initiative.de/fhir/ext/modul-molgen/StructureDefinition/therapeutische-implikation",
      "http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/therapeutic-implication"
    ]
  },
  "code": {
    "coding": [
      {
        "system": "http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs",
        "code": "therapeutic-implication",
        "display": "Therapeutische Implikation"
      }
    ]
  },
  "category": [
    {
      "coding": [
        {
          "system": "http://terminology.hl7.org/CodeSystem/observation-category",
          "code": "laboratory",
          "display": "Laboratory"
        }
      ]
    },
    {
      "coding": [
        {
          "system": "http://terminology.hl7.org/CodeSystem/v2-0074",
          "code": "GE"
        }
      ]
    }
  ],
  "component": [
    {
      "code": {
        "coding": [
          {
            "system": "http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs",
            "code": "conclusion-string"
          }
        ]
      },
      "valueString": "Hochselektiver FGFR2-Inhibitor RLY-4008 bei Patienten mit Cholangiokarzinomen und anderen soliden Tumoren, mit oder ohne FGFR- gerichtete Vortherapie."
    },
    {
      "code": {
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "51963-7",
            "display": "Medication assessed [ID]"
          }
        ]
      },
      "valueCodeableConcept": {
        "coding": [
          {
            "code": "L01EN",
            "system": "http://www.whocc.no/atc",
            "display": "Fibroblasten-Wachstumsfaktor-Rezeptor (FGFR)-Tyrosinkinase-Inhibitoren"
          },
          {
            "code": "1162485005",
            "system": "http://snomed.info/sct",
            "display": "Substance with fibroblast growth factor receptor inhibitor mechanism of action (substance)"
          }
        ]
      }
    },
    {
      "code": {
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "93044-6"
          }
        ]
      },
      "valueCodeableConcept": {
        "text": "m1c"
      }
    },
    {
      "code": {
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "81259-4"
          }
        ]
      },
      "valueCodeableConcept": {
        "coding": [
          {
            "code": "109842005",
            "system": "http://snomed.info/sct",
            "display": "Intrahepatic bile duct carcinoma (disorder)"
          },
          {
            "code": "C22.1",
            "system": "http://fhir.de/CodeSystem/bfarm/icd-10-gm",
            "display": "Intrahepatisches Gallengangskarzinom"
          }
        ]
      }
    }
  ],
  "status": "final",
  "subject": {
    "reference": "Patient/mii-exa-molgen-patient-fgfr2-fusion"
  },
  "performer": [
    {
      "reference": "Practitioner/mii-exa-molgen-practitioner-lab"
    }
  ],
  "derivedFrom": [
    {
      "reference": "Observation/mii-exa-molgen-variante-fgfr2-fusion"
    }
  ]
}
